Eterna Therapeutics Stock Performance
| ERNA Stock | USD 0.33 0.01 2.94% |
The firm shows a Beta (market volatility) of 0.75, which means possible diversification benefits within a given portfolio. As returns on the market increase, Eterna Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Eterna Therapeutics is expected to be smaller as well. At this point, Eterna Therapeutics has a negative expected return of -2.12%. Please make sure to confirm Eterna Therapeutics' information ratio, skewness, day typical price, as well as the relationship between the treynor ratio and daily balance of power , to decide if Eterna Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Eterna Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:20 | Last Split Date 2022-10-17 |
1 | 12 Health Care Stocks Moving In Wednesdays Intraday Session - Benzinga | 09/25/2024 |
2 | StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics | 10/08/2024 |
3 | Acquisition by Singer Nicholas Jason of 212464 shares of Eterna Therapeutics at 3.28 subject to Rule 16b-3 | 10/10/2024 |
4 | Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune... | 10/17/2024 |
5 | Disposition of 3125976 shares by Cherington Charles of Eterna Therapeutics at 1.43 subject to Rule 16b-3 | 10/29/2024 |
6 | Eterna Therapeutics shareholder Charles Cherington sells 6.54m in stock | 11/05/2024 |
7 | ERNA Stock Hits 52-Week Low at 0.83 Amid Market Challenges - Investing.com | 11/15/2024 |
8 | Eterna Therapeutics Announces Up to 1 Million Stock Repurchase Program | 11/25/2024 |
9 | BTX Precision Announces Acquisition of Addison Precision Manufacturing | 12/10/2024 |
| Begin Period Cash Flow | 15.5 M |
Eterna |
Eterna Therapeutics Relative Risk vs. Return Landscape
If you would invest 153.00 in Eterna Therapeutics on September 12, 2024 and sell it today you would lose (120.00) from holding Eterna Therapeutics or give up 78.43% of portfolio value over 90 days. Eterna Therapeutics is currently does not generate positive expected returns and assumes 7.6784% risk (volatility on return distribution) over the 90 days horizon. In different words, 68% of stocks are less volatile than Eterna, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Eterna Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Eterna Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Eterna Therapeutics, and traders can use it to determine the average amount a Eterna Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2761
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ERNA |
Estimated Market Risk
| 7.68 actual daily | 68 68% of assets are less volatile |
Expected Return
| -2.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.28 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Eterna Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Eterna Therapeutics by adding Eterna Therapeutics to a well-diversified portfolio.
Eterna Therapeutics Fundamentals Growth
Eterna Stock prices reflect investors' perceptions of the future prospects and financial health of Eterna Therapeutics, and Eterna Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Eterna Stock performance.
| Return On Equity | -11.54 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (104.91) % | ||||
| Current Valuation | 49.83 M | ||||
| Shares Outstanding | 51.37 M | ||||
| Price To Book | 2.10 X | ||||
| Price To Sales | 106.24 X | ||||
| Revenue | 68 K | ||||
| EBITDA | (19.93 M) | ||||
| Net Income | (21.67 M) | ||||
| Cash And Equivalents | 19.41 M | ||||
| Cash Per Share | 6.60 X | ||||
| Total Debt | 41.84 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 3.08 X | ||||
| Book Value Per Share | 0.41 X | ||||
| Cash Flow From Operations | (20.41 M) | ||||
| Earnings Per Share | (8.31) X | ||||
| Market Capitalization | 17.21 M | ||||
| Total Asset | 49.13 M | ||||
| Retained Earnings | (186.98 M) | ||||
| Working Capital | 3.03 M | ||||
About Eterna Therapeutics Performance
By analyzing Eterna Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Eterna Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Eterna Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Eterna Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (803.18) | (763.02) | |
| Return On Tangible Assets | (0.46) | (0.48) | |
| Return On Capital Employed | (0.50) | (0.52) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (9.70) | (9.22) |
Things to note about Eterna Therapeutics performance evaluation
Checking the ongoing alerts about Eterna Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Eterna Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Eterna Therapeutics generated a negative expected return over the last 90 days | |
| Eterna Therapeutics has high historical volatility and very poor performance | |
| Eterna Therapeutics has some characteristics of a very speculative penny stock | |
| Eterna Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 68 K. Net Loss for the year was (21.67 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eterna Therapeutics currently holds about 19.41 M in cash with (20.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.6, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Eterna Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from newswire.com: BTX Precision Announces Acquisition of Addison Precision Manufacturing |
- Analyzing Eterna Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Eterna Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Eterna Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Eterna Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Eterna Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Eterna Therapeutics' stock. These opinions can provide insight into Eterna Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Eterna Stock analysis
When running Eterna Therapeutics' price analysis, check to measure Eterna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eterna Therapeutics is operating at the current time. Most of Eterna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Eterna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eterna Therapeutics' price. Additionally, you may evaluate how the addition of Eterna Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |